Home › Funds › Lion Point Capital, LP › DYN

Lion Point Capital, LP position in DYN

DYNE THERAPEUTICS INC · Health Care

Lion Point Capital, LP reported holding 18,000 shares of DYN (DYNE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$400K, representing 1.91% of its reported portfolio and ranking #20 among its reported holdings. Lion Point Capital, LP has disclosed DYN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)18.00K sh
Reported value held$399.78K
Portfolio Weight1.91%
First reportedQ4 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Lion Point Capital, LP's DYN position evolved

Lion Point Capital, LP first disclosed a stake in DYN in Q4 2025 at 18,000 shares (US$352K). The position peaked in Q2 2026 at 18,000 shares, worth US$400K. Across 3 filings, Lion Point Capital, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 18,000 shares valued at US$400K.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 18.00K $352.08K New
Q1 2026 18.00K $326.34K Hold
Q2 2026 18.00K $399.78K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DYN and 13F data

DYN (DYNE THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in DYN — the largest reported positions include Atlas Venture Life Science Advisors, LLC (US$151.0M), TCG Crossover Management, LLC (US$102.5M), FCPM III SERVICES B.V. (US$85.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DYN

All DYN fund holders →

FAQ

How long has Lion Point Capital, LP held DYN?

Lion Point Capital, LP has disclosed DYN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Lion Point Capital, LP's current position in DYN?

As of Q2 2026, Lion Point Capital, LP holds 18.00K shares of DYN (DYNE THERAPEUTICS INC), valued at $399.78K, representing 1.91% of its reported portfolio and ranking #20.

Has Lion Point Capital, LP been buying or selling DYN?

In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in DYN. The position peaked in Q2 2026 at 18.00K shares.

Which other funds hold DYN?

Other major institutional holders of DYN include Atlas Venture Life Science Advisors, LLC, TCG Crossover Management, LLC, FCPM III SERVICES B.V., among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.